कंपनी का अवलोकन
iTonic Holdings Ltd. is a healthcare solutions provider that specializes in the development and commercialization of treatment software and devices specifically designed for brachytherapy applications. The company's proprietary treatment planning system facilitates radioactive particle implantation, a form of radiotherapy utilized for treating cancer patients by strategically placing radioactive sources within the body. Operating within the Healthcare sector and the Medical Devices industry, the firm focuses on advancing medical technologies that address oncological needs. With a market capitalization of $7.42M and annual revenue of $523,031, the company maintains a very small operational footprint supported by a workforce of only 7 employees. These financial figures indicate that iTonic Holdings Ltd. functions as a micro-cap entity, suggesting it is in a nascent stage of commercialization where revenue generation is currently limited relative to its market valuation. The disparity between its market cap and revenue highlights the market's pricing in high future growth potential or specific niche technological assets rather than current profitability.
वित्तीय स्वास्थ्य
The company reported revenue of $523,031 for the trailing twelve months, yet posted a net income of $-5,097,901, revealing a severe structural gap where costs significantly outweigh income. EBITDA stood at $-5,173,649, further confirming that operating expenses are draining value from the core business activities before interest and taxes are applied. Free cash flow was negative at $-902,183, indicating that the company is burning cash and lacks immediate financial flexibility to fund operations without external capital injections. Gross margin is recorded at 62.6%, which suggests a high pricing power or low cost of goods sold on the products sold, while the operating margin of -681.9% and profit margin of 0.0% demonstrate that overhead costs and research expenses are disproportionately high relative to sales. In terms of solvency, the company holds $2.93M in cash against $142,998 in debt, resulting in a debt-to-equity ratio of 1.76. Although the absolute debt level is low, the high debt-to-equity ratio implies a leveraged balance sheet relative to shareholder equity, yet the substantial cash reserve provides a significant buffer against short-term obligations. The current ratio stands at 8.83, indicating a highly liquid balance sheet with current assets vastly exceeding current liabilities. However, the return on equity is -71.2% and the return on assets is -41.0%, revealing that management is currently destroying shareholder value and failing to generate positive returns on the capital employed in the business.
मूल्यांकन आकलन
Trailing P/E and forward P/E ratios are listed as N/A due to the company's negative earnings history, meaning traditional earnings-based valuation metrics are not applicable for assessing current value. Despite the lack of earnings-based multiples, the price-to-book ratio is 0.70, indicating that the stock is trading below its book value per share. The price-to-sales ratio is 14.18, which suggests the market is valuing the company at a significant premium to its revenue, likely based on expectations of future profitability or the strategic value of its medical device patents. The EV/EBITDA metric is -0.84, reflecting the negative earnings quality and the fact that enterprise value cannot be normalized by earnings in this stage of development. The stock has exhibited extreme volatility, trading between a 52-week high of $32.00 and a 52-week low of $0.25. While the exact current price is not explicitly defined in the provided facts, the wide range indicates that the security is currently trading in a highly speculative environment relative to its historical bounds. A beta value is listed as N/A, implying that the company's price volatility is not statistically correlated with the broader market index in a standard manner, or data is insufficient to calculate this metric.
Growth & Income
Revenue growth year-over-year accelerated significantly to 91.6%, suggesting a rapid expansion in sales volume or a successful launch of new product lines within the brachytherapy market. Earnings growth is listed as N/A due to the negative net income, which prevents a direct comparison of profitability growth against revenue growth. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders. Instead, the firm retains all earnings and negative cash flows to reinvest into research, development, and commercialization efforts required to scale its medical device portfolio. The absence of dividend payments aligns with the company's growth strategy, where capital is prioritized for operational expansion rather than income distribution to investors. This growth and income profile characterizes iTonic Holdings Ltd. as a pure-play growth stock with no current income component, relying entirely on capital appreciation driven by future financial performance.